A PYMNTS Company

Sanofi In Deal To Buy Biotech Company for $3.4B

By  |  August 17, 2020

Sanofi agreed to acquire US biotech company Principia Biopharma for about US$3.4 billion as the French drugmaker pivots toward innovative therapies to spur growth under new Chief Executive Officer Paul Hudson.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The all-cash deal will see Sanofi taking full control of the company, which focuses on treatments for multiple sclerosis and a range of autoimmune disorders, according to a statement Monday, August 17. Bloomberg reported last month that Sanofi was studying potential acquisitions of US biotechnology firms, including Principia.

    Sanofi said in a statement that it would pay for the acquisition out of its cash reserves and would offer US$100 per share to Principia’s shareholders, which represents a roughly 10% premium from Friday’s closing price, reported The Financial Times. 

    If the acquisition is completed as planned by the end of 2020, Sanofi would save on those payments.

    Full Content: Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.